Direct costs – diabetes-associated costs: Associated healthcare costs were assessed as excess costs by three studies [51–53], ranging between €1958.33 for patients newly treated for type 2 diabetes [51] and €4050.45 for patients treated with insulin [53] (Table 2, Fig. 3). This evidence concerns the gene INS and type 2 diabetes mellitus.